» Articles » PMID: 38069396

Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Dec 9
PMID 38069396
Authors
Affiliations
Soon will be listed here.
Abstract

This paper introduces the reader to the field of liquid biopsies and cell-free nucleic acids, focusing on circulating tumor DNA (ctDNA) in breast cancer (BC). BC is the most common type of cancer in women, and progress with regard to treatment has been made in recent years. Despite this, there remain a number of unresolved issues in the treatment of BC; in particular, early detection and diagnosis, reliable markers of response to treatment and for the prediction of recurrence and metastasis, especially for unfavorable subtypes, are needed. It is also important to identify biomarkers for the assessment of drug resistance and for disease monitoring. Our work is devoted to ctDNA, which may be such a marker. Here, we describe its main characteristics and potential applications in clinical oncology. This review considers the results of studies devoted to the analysis of the prognostic and predictive roles of various methods for the determination of ctDNA in BC patients. Currently known epigenetic changes in ctDNA with clinical significance are reviewed. The possibility of using ctDNA as a predictive and prognostic marker for monitoring BC and predicting the recurrence and metastasis of cancer is also discussed, which may become an important part of a precision approach to the treatment of BC.

Citing Articles

LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.

Arima J, Yoshino H, Fukumoto W, Kawahara I, Saito S, Li G Int J Mol Sci. 2024; 25(11).

PMID: 38892143 PMC: 11172611. DOI: 10.3390/ijms25115955.


Molecular methods in cancer diagnostics: a short review.

Budhbaware T, Rathored J, Shende S Ann Med. 2024; 56(1):2353893.

PMID: 38753424 PMC: 11100444. DOI: 10.1080/07853890.2024.2353893.


Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report.

Capella M, Fallah P, Basik M Oncol Lett. 2024; 27(6):282.

PMID: 38736743 PMC: 11082640. DOI: 10.3892/ol.2024.14415.


Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.

Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M Front Oncol. 2024; 14:1303335.

PMID: 38333685 PMC: 10850354. DOI: 10.3389/fonc.2024.1303335.

References
1.
Zhao Y, OKeefe C, Hsieh K, Cope L, Joyce S, Pisanic T . Multiplex Digital Methylation-Specific PCR for Noninvasive Screening of Lung Cancer. Adv Sci (Weinh). 2023; 10(16):e2206518. PMC: 10238189. DOI: 10.1002/advs.202206518. View

2.
Jatoi I, Anderson W, Jeong J, Redmond C . Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011; 29(17):2301-4. PMC: 3107746. DOI: 10.1200/JCO.2010.32.3550. View

3.
Brenne S, Madsen P, Pedersen I, Hveem K, Skorpen F, Krarup H . Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study. Br J Cancer. 2023; 129(5):861-868. PMC: 10449868. DOI: 10.1038/s41416-023-02337-4. View

4.
Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A . Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 2017; 9(1):115. PMC: 5740791. DOI: 10.1186/s13073-017-0499-9. View

5.
Yi Z, Ma F, Rong G, Guan Y, Li C, Xu B . Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. Cancer Commun (Lond). 2020; 40(6):260-269. PMC: 7307233. DOI: 10.1002/cac2.12032. View